Screener
Theravance Biopharma TBPH PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Other prepaid and current assets | 7,384 | 7,564 |
| Total current assets | 417,634 | 418,460 |
| Long-term marketable securities | — | 11,128 |
| Property and equipment, net | 5,539 | 5,895 |
| Operating lease assets | 23,001 | 24,371 |
| Restricted cash | 836 | 836 |
| Other assets | 25,303 | 24,880 |
| Total assets | $472,313 | $485,570 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's PP&E (net)?
- Theravance Biopharma (TBPH) reported PP&E (net) of $5.54M in Q1 2026.
- How has Theravance Biopharma's PP&E (net) changed year-over-year?
- Theravance Biopharma's PP&E (net) decreased by 21.2% year-over-year, from $7.03M to $5.54M.
- What is the long-term trend for Theravance Biopharma's PP&E (net)?
- Over 5 years (2020 to 2025), Theravance Biopharma's PP&E (net) has grown at a -18.5% compound annual growth rate (CAGR), from $16.42M to $5.9M.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Theravance Biopharma's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude